Differentiating Prescribed Medications from False Positive Drug Screens

Understanding the Two-Tier Testing System

• Labs distinguish prescribed medications from false positives by using confirmatory testing with gas chromatography-mass spectrometry (GC-MS), which can definitively identify specific drug molecules and differentiate them from structurally similar compounds that cause cross-reactivity on initial immunoassay screens 1, 2
• Immunoassay screening tests are presumptive only and have inherent limitations in specificity due to cross-reactivity with structurally similar compounds 1, 2, 3
• Gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) can positively identify specific substances and generate quantitative concentrations 1, 2
• These confirmatory methods are selective enough to differentiate specific opioids and metabolites from one another 4
• LC-MS/MS has detection limits typically less than 1 ng/mL and can detect all classes of medications or their metabolites 5

Common Medications Causing False Positives

• Pseudoephedrine (in over-the-counter cold medications) causes false positive amphetamine results 3, 6
• Trazodone (via its metabolite m-CPP) causes false positive amphetamine/methamphetamine results 7
• Fluoroquinolone antibiotics cross-react with opiate immunoassay screens 6
• Poppy seed ingestion causes false positives for morphine and codeine on both screening and confirmatory tests 3
• Standard immunoassays may not detect semisynthetic opioids like oxycodone, and hydromorphone (a metabolite of hydrocodone) can be confused with actual hydromorphone use 4
• Dextromethorphan (cough suppressant) can cause false positives 3

Critical Clinical Approach

• Obtain complete medication history including all prescription medications, over-the-counter drugs, and supplements before interpreting any positive drug test 3, 6
• Document this medication list on the laboratory request form 5
• Discuss unexpected results with the local laboratory or toxicologist before making clinical decisions 4, 6
• Request confirmatory GC-MS testing when results are unexpected or will impact patient management 3, 6
• Never make consequential clinical decisions (such as discharging patients from care, child custody implications, or legal actions) based solely on immunoassay results without confirmation 6, 7

Important Pitfalls to Avoid

• Never assume immunoassay results are definitive—they are screening tests only with known limitations 1, 2, 3
• Do not dismiss patients from care based on urine drug test results, as this constitutes patient abandonment 4
• Recognize that timing of medication use relative to testing affects detection windows 5
• Be aware that standard panels often don't include commonly abused substances like fentanyl, buprenorphine, MDMA, or ketamine 3
• Pain medications given during delivery can cause false positives, so testing should occur before administering such medications when possible 3

Appropriate Sequencing of Drug Testing

Introduction to Sequential Testing

• The Centers for Disease Control and Prevention recommends that definitive testing should be guided by the results of presumptive testing, with confirmatory testing using gas chromatography/mass spectrometry based on unexpected immunoassay results or when specific opioids cannot be identified on standard immunoassays 8, 9
• Clinicians should not test for substances for which results would not affect patient management, and restricting confirmatory testing to situations where results can reasonably affect management reduces costs 8

Clinical Guideline Support

• The American Medical Association suggests that initial presumptive testing (immunoassay) should be used to screen for commonly prescribed opioids and illicit drugs, followed by review and interpretation of presumptive results with consideration of the patient's medication history and clinical context 9, 8
• Confirmatory definitive testing should only be performed when indicated by unexpected presumptive results, need to identify specific opioids not detectable on immunoassay, or when results will directly inform clinical decision-making 8, 9

Cost-Effectiveness and Medical Necessity

• The Centers for Disease Control and Prevention states that performing both tests simultaneously violates the fundamental principle of cost-effective, evidence-based medicine, as many presumptive results will be as expected, making confirmatory testing unnecessary 8, 9
• Confirmatory testing adds substantial costs and should only be performed when clinically indicated, with blanket definitive testing without regard to presumptive results representing overutilization that does not improve patient safety or clinical outcomes 8

Comprehensive Monitoring

• The Infectious Diseases Society of America recommends universal urine drug testing for patients on chronic opioid therapy, but this refers to the practice of testing all patients, not performing all possible tests simultaneously 10, 11, 9
• Baseline and periodic monitoring (every 6-12 months for stable patients) can be accomplished with presumptive testing alone when results are as expected 10, 11, 12

Hydrocodone Detection Limitations

Understanding Standard Drug Testing Limitations

• Standard opiate immunoassays are designed to detect morphine and codeine, creating a critical gap in detecting commonly prescribed synthetic opioids, such as hydrocodone, in patients, according to The Lancet Child and Adolescent Health 13, 14, 15
• Only morphine and codeine are reliably detected on routine screening, which may lead to false negatives for hydrocodone use in the general population 13, 14
• A negative standard opiate screen does not rule out hydrocodone use in individuals, highlighting the need for specific testing 14

Detection Requirements for Hydrocodone

• To detect Norco/hydrocodone, specific testing must be ordered separately, as standard panels do not include synthetic opioids, affecting the accuracy of drug screens for patients 13, 14
• Standard panels require supplementation with synthetic opioid testing to ensure accurate detection of hydrocodone use in the population 13, 14
• The metabolite hydromorphone is detectable for 1-2 days after hydrocodone use in most individuals, which is essential for monitoring compliance 13

Confirmatory Testing is Essential

• Gas chromatography-mass spectrometry (GC-MS) should be used to confirm any unexpected results before making clinical decisions regarding patient care, as recommended by JAMA 16
• GC-MS can definitively identify specific opioids, such as hydrocodone, and differentiate them from cross-reacting substances in patients, ensuring accurate diagnosis and treatment 16

Practical Clinical Approach

• Verify what substances are included in the testing panel before ordering, to ensure that hydrocodone/hydromorphone are included, which is crucial for accurate monitoring of patients 13, 14
• Never make clinical decisions based on immunoassay results alone, as they may be prone to false positives and false negatives, and consider consulting with laboratory toxicologists for guidance on interpreting results 16
• Order GC-MS confirmation when results are unexpected or will impact patient management, to ensure accurate diagnosis and treatment 16

Hydrocodone and Oxycodone Detection in Urine Drug Screens

Understanding the Critical Testing Limitations

• Standard opiate immunoassays are designed to detect morphine and codeine, creating a critical gap in detecting commonly prescribed synthetic opioids like both hydrocodone and oxycodone, according to the Lancet Child and Adolescent Health 17
• Standard immunoassays do not consistently detect hydrocodone, oxycodone, hydromorphone, or methadone—gas chromatography or mass spectrometry is required to identify these specific substances, as recommended by the Annals of Internal Medicine 18

The Metabolite Detection Pattern

• Hydromorphone (a metabolite of hydrocodone) can be confused with actual hydromorphone use, but the presence of norhydrocodone confirms hydrocodone as the source drug, according to the Annals of Internal Medicine 18

Critical Pitfalls to Avoid

• Request confirmatory GC-MS or LC-MS/MS testing when results are unexpected or will impact patient management, as recommended by the Annals of Internal Medicine 18